{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T10:34:36Z","timestamp":1793183676222,"version":"4.5.0"},"reference-count":169,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T00:00:00Z","timestamp":1703894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T00:00:00Z","timestamp":1703894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40257-023-00836-x","type":"journal-article","created":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T10:02:12Z","timestamp":1703930532000},"page":"243-259","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Pityriasis Rubra Pilaris: An Updated Review of Clinical Presentation, Etiopathogenesis, and Treatment Options"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7897-2940","authenticated-orcid":false,"given":"Tejas P.","family":"Joshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,30]]},"reference":[{"key":"836_CR1","first-page":"648","volume":"2","author":"C Tarral","year":"1835","unstructured":"Tarral C. General psoriasis. Desquamation from the parts covered with hair. Theor Pract Treatise Dis Skin. 1835;2:648\u20139.","journal-title":"Theor Pract Treatise Dis Skin."},{"key":"836_CR2","first-page":"197","volume":"3","author":"M Devergie","year":"1856","unstructured":"Devergie M. Pityriasis pilaris, maladie de peau non decrite par les dermatologistes. Gaz Hebd Med Chir. 1856;3:197\u2013201.","journal-title":"Gaz Hebd Med Chir."},{"key":"836_CR3","unstructured":"Besnier E. Observations pour servir \u00e0 l\u2019histoire clinique du pityriasis rubra pilaire. Ann Derm Syph Ser. 1889;10."},{"key":"836_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40257-017-0338-1","volume":"19","author":"D Wang","year":"2018","unstructured":"Wang D, Chong VC-L, Chong W-S, Oon HH. A review on pityriasis rubra pilaris. Am J Clin Dermatol. 2018;19:377\u201390.","journal-title":"Am J Clin Dermatol"},{"key":"836_CR5","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/j.1365-2133.1989.tb08229.x","volume":"121","author":"VN Sehgal","year":"1989","unstructured":"Sehgal VN, Jain MK, Mathur RP. Pityriasis rubra pilaris in Indians. Br J Dermatol. 1989;121:821\u20132.","journal-title":"Br J Dermatol"},{"key":"836_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1365-2230.1980.tb01676.x","volume":"5","author":"WA Griffiths","year":"1980","unstructured":"Griffiths WA. Pityriasis rubra pilaris. Clin Exp Dermatol. 1980;5:105\u201312.","journal-title":"Clin Exp Dermatol"},{"key":"836_CR7","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1001\/jamadermatol.2016.0091","volume":"152","author":"NA Ross","year":"2016","unstructured":"Ross NA, Chung H-J, Li Q, Andrews JP, Keller MS, Uitto J. Epidemiologic, clinicopathologic, diagnostic, and management challenges of pityriasis rubra pilaris: a case series of 100 patients. JAMA Dermatol. 2016;152:670\u20135.","journal-title":"JAMA Dermatol"},{"key":"836_CR8","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1365-4632.2012.05811.x","volume":"53","author":"N Marrouche","year":"2014","unstructured":"Marrouche N, Kurban M, Kibbi A-G, Abbas O. Pityriasis rubra pilaris: clinicopathological study of 32 cases from Lebanon. Int J Dermatol. 2014;53:434\u20139.","journal-title":"Int J Dermatol"},{"key":"836_CR9","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.jaad.2021.03.043","volume":"86","author":"S Ghatnekar","year":"2022","unstructured":"Ghatnekar S, Shah N, Min MS, Mazori DR, LaChance AH, Vleugels RA, et al. Clinical features and eosinophilia in pityriasis rubra pilaris: a multicenter cohort. J Am Acad Dermatol. 2022;86:907\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"836_CR10","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1001\/jamadermatol.2020.3426","volume":"156","author":"K Halper","year":"2020","unstructured":"Halper K, Wright B, Maloney NJ, Kim MM, Ravi V, Worswick S, et al. Characterizing disease features and other medical diagnoses in patients with pityriasis rubra pilaris. JAMA Dermatol. 2020;156:1373\u20134.","journal-title":"JAMA Dermatol"},{"key":"836_CR11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ijwd.2021.01.010","volume":"7","author":"JG Plante","year":"2021","unstructured":"Plante JG, Aleisa AI, Thiers BH. Pityriasis rubra pilaris in skin of color. Int J Womens Dermatol. 2021;7:207\u20138.","journal-title":"Int J Womens Dermatol."},{"key":"836_CR12","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0190-9622(86)70256-9","volume":"15","author":"TS Sonnex","year":"1986","unstructured":"Sonnex TS, Dawber RP, Zachary CB, Millard PR, Griffiths AD. The nails in adult type 1 pityriasis rubra pilaris: a comparison with S\u00e9zary syndrome and psoriasis. J Am Acad Dermatol. 1986;15:956\u201360.","journal-title":"J Am Acad Dermatol"},{"key":"836_CR13","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/j.jaad.2022.07.039","volume":"87","author":"A Ji-Xu","year":"2022","unstructured":"Ji-Xu A, Lei DK, Maloney NJ, Worswick S. Clinical course, diagnostic patterns, and treatment outcomes in patients with pityriasis rubra pilaris. J Am Acad Dermatol. 2022;87:1450\u20131.","journal-title":"J Am Acad Dermatol"},{"key":"836_CR14","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1111\/ced.15378","volume":"47","author":"J-Y Wong","year":"2022","unstructured":"Wong J-Y, Surgenor L, McCourt C. Pityriasis rubra pilaris with erythema gyratum repens-like eruption and resolution with ustekinumab. Clin Exp Dermatol. 2022;47:2300\u20133.","journal-title":"Clin Exp Dermatol"},{"key":"836_CR15","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.jdcr.2018.07.009","volume":"4","author":"PM Richey","year":"2018","unstructured":"Richey PM, Fairley JA, Stone MS. Transformation from pityriasis rubra pilaris to erythema gyratum repens-like eruption without associated malignancy: a report of 2 cases. JAAD Case Rep. 2018;4:944\u20136.","journal-title":"JAAD Case Rep."},{"key":"836_CR16","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1111\/jdv.16785","volume":"35","author":"AD Gloor","year":"2021","unstructured":"Gloor AD, van Rhyn M, Schlapbach C. Erythema gyratum repens-like eruption after anti-IL-17 therapy of pityriasis rubra pilaris. J Eur Acad Dermatol Venereol. 2021;35:e38-40.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"836_CR17","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/ajd.12752","volume":"59","author":"R Davenport","year":"2018","unstructured":"Davenport R, Le ST, Gin A, Goh MS, Foley P. Resolving classic pityriasis rubra pilaris, mimicker of erythema gyratum repens. Australas J Dermatol. 2018;59:232\u20133.","journal-title":"Australas J Dermatol"},{"issue":"23","key":"836_CR18","first-page":"02865","volume":"S0190\u20139622","author":"RC Velasco","year":"2023","unstructured":"Velasco RC, Shao C, Greiling TM. Patient-reported cutaneous signs and symptoms of adult pityriasis rubra pilaris and correlation with quality of life and clinician-reported severity: a cross-sectional study. J Am Acad Dermatol. 2023;S0190\u20139622(23):02865\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"836_CR19","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.jaad.2008.07.054","volume":"59","author":"C-C Yang","year":"2008","unstructured":"Yang C-C, Shih I-H, Lin W-L, Yu Y-S, Chiu H-C, Huang P-H, et al. Juvenile pityriasis rubra pilaris: report of 28 cases in Taiwan. J Am Acad Dermatol. 2008;59:943\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"836_CR20","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1067\/mjd.2002.124619","volume":"47","author":"DS Allison","year":"2002","unstructured":"Allison DS, El-Azhary RA, Calobrisi SD, Dicken CH. Pityriasis rubra pilaris in children. J Am Acad Dermatol. 2002;47:386\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"836_CR21","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1525-1470.1986.tb00648.x","volume":"3","author":"C Gelmetti","year":"1986","unstructured":"Gelmetti C, Schiuma AA, Cerri D, Gianotti F. Pityriasis rubra pilaris in childhood: a long-term study of 29 cases. Pediatr Dermatol. 1986;3:446\u201351.","journal-title":"Pediatr Dermatol"},{"key":"836_CR22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/j.1365-2230.1994.tb01141.x","volume":"19","author":"T Piamphongsant","year":"1994","unstructured":"Piamphongsant T, Akaraphant R. Pityriasis rubra pilaris: a new proposed classification. Clin Exp Dermatol. 1994;19:134\u20138.","journal-title":"Clin Exp Dermatol"},{"key":"836_CR23","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1177\/1203475418775378","volume":"22","author":"ME MacGillivray","year":"2018","unstructured":"MacGillivray ME, Fiorillo L. Recurrent pityriasis rubra pilaris: a case report. J Cutan Med Surg. 2018;22:624\u20136.","journal-title":"J Cutan Med Surg"},{"key":"836_CR24","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S0190-9622(89)80284-1","volume":"21","author":"DG Lambert","year":"1989","unstructured":"Lambert DG, Dalac S. Nail changes in type 5 pityriasis rubra pilaris. J Am Acad Dermatol. 1989;21:811\u20132.","journal-title":"J Am Acad Dermatol"},{"key":"836_CR25","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/0190-9622(91)70106-C","volume":"24","author":"A Blauvelt","year":"1991","unstructured":"Blauvelt A, Nahass GT, Pardo RJ, Kerdel FA. Pityriasis rubra pilaris and HIV infection. J Am Acad Dermatol. 1991;24:703\u20135.","journal-title":"J Am Acad Dermatol"},{"key":"836_CR26","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/j.1365-2133.1995.tb06939.x","volume":"133","author":"ES Miralles","year":"1995","unstructured":"Miralles ES, N\u00fa\u00f1ez M, De Las Heras ME, P\u00e9rez B, Moreno R, Ledo A. Pityriasis rubra pilaris and human immunodeficiency virus infection. Br J Dermatol. 1995;133:990\u20133.","journal-title":"Br J Dermatol"},{"key":"836_CR27","first-page":"522","volume":"63","author":"PA Nair","year":"2018","unstructured":"Nair PA, Sheth N. Atypical adult-onset pityriasis rubra pilaris in an HIV-positive adult male. Indian J Dermatol. 2018;63:522\u20134.","journal-title":"Indian J Dermatol"},{"key":"836_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jdcr.2022.07.015","volume":"27","author":"A Kranyak","year":"2022","unstructured":"Kranyak A, Shuler M. Pityriasis rubra pilaris rapidly cleared with ixekizumab in an HIV-positive patient. JAAD Case Rep. 2022;27:55\u20137.","journal-title":"JAAD Case Rep."},{"key":"836_CR29","doi-asserted-by":"publisher","first-page":"100","DOI":"10.4103\/ijstd.IJSTD_120_15","volume":"41","author":"A Williams","year":"2020","unstructured":"Williams A, George A, Thomas EA, Koshy JM. Pityriasis rubra pilaris type 6: a case report in an AIDS patient. Indian J Sex Transm Dis AIDS. 2020;41:100\u20131.","journal-title":"Indian J Sex Transm Dis AIDS."},{"key":"836_CR30","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jaad.2018.02.034","volume":"79","author":"BG Craiglow","year":"2018","unstructured":"Craiglow BG, Boyden LM, Hu R, Virtanen M, Su J, Rodriguez G, et al. CARD14-associated papulosquamous eruption: a spectrum including features of psoriasis and pityriasis rubra pilaris. J Am Acad Dermatol. 2018;79:487\u201394.","journal-title":"J Am Acad Dermatol"},{"key":"836_CR31","doi-asserted-by":"crossref","unstructured":"Li N, Tao J, Zhang J, Liu Z, Yu P. A novel mutation in a CARD14-associated papulosquamous eruption. Pediatr Dermatol. 2023;40:706\u20139.","DOI":"10.1111\/pde.15254"},{"key":"836_CR32","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1111\/jdv.16799","volume":"35","author":"T Takeichi","year":"2021","unstructured":"Takeichi T, Terawaki S, Kubota Y, Ito Y, Tanahashi K, Muro Y, et al. A patient with CARD14-associated papulosquamous eruptions showing atopic dermatitis-like features. J Eur Acad Dermatol Venereol. 2021;35:e58\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"836_CR33","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1365-4632.2009.04206.x","volume":"49","author":"CJ Ko","year":"2010","unstructured":"Ko CJ, Heald P, Antaya RJ, Bolognia JL. Facial discoid dermatosis. Int J Dermatol. 2010;49:189\u201392.","journal-title":"Int J Dermatol"},{"key":"836_CR34","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/1346-8138.13045","volume":"42","author":"A Salman","year":"2015","unstructured":"Salman A, Tekin B, Berenjian A, Cinel L, Demirkesen C. Facial discoid dermatosis: a further case of a novel entity. J Dermatol. 2015;42:1132\u20133.","journal-title":"J Dermatol"},{"key":"836_CR35","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/ced.13611","volume":"43","author":"M Bohdanowicz","year":"2018","unstructured":"Bohdanowicz M, DeKoven JG. Improvement in facial discoid dermatosis with calcipotriol\/betamethasone ointment and low-dose acitretin. Clin Exp Dermatol. 2018;43:820\u20131.","journal-title":"Clin Exp Dermatol"},{"issue":"20","key":"836_CR36","first-page":"30549","volume":"S0001\u20137310","author":"L Condal","year":"2020","unstructured":"Condal L, Quer A, Ferr\u00e1ndiz C, Bielsa I. Facial discoid dermatosis: an enigmatic disease. Actas Dermosifiliogr (Engl Ed). 2020;S0001\u20137310(20):30549\u201354.","journal-title":"Actas Dermosifiliogr (Engl Ed)."},{"key":"836_CR37","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/ced.14945","volume":"47","author":"R Amarnani","year":"2022","unstructured":"Amarnani R, Hughes S, Morris-Jones R, Kanwar AJ, Bunker CB. Persistent facial discoid dermatosis successfully treated with topical calcipotriol. Clin Exp Dermatol. 2022;47:229\u201331.","journal-title":"Clin Exp Dermatol"},{"key":"836_CR38","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/cup.14190","volume":"49","author":"M Welborn","year":"2022","unstructured":"Welborn M, Fletcher D, Motaparthi K. Atrophy of sebaceous lobules in facial discoid dermatosis: a link to psoriasis and seborrheic dermatitis? J Cutan Pathol. 2022;49:320\u20133.","journal-title":"J Cutan Pathol"},{"key":"836_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.56","volume":"1","author":"S Rahmatulla","year":"2021","unstructured":"Rahmatulla S, Batta K, Tatnall F, Sandhu D, Brown V. Facial discoid dermatosis: a cosmetically disfiguring and challenging condition to treat. Skin Health Dis. 2021;1: e56.","journal-title":"Skin Health Dis."},{"key":"836_CR40","first-page":"174","volume":"20","author":"AG Zaladonis","year":"2022","unstructured":"Zaladonis AG, Lee JB, Hsu S, Motaparthi K. Facial discoid dermatosis: what is it? Skinmed. 2022;20:174\u20136.","journal-title":"Skinmed."},{"key":"836_CR41","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/cup.13148","volume":"45","author":"EY Gan","year":"2018","unstructured":"Gan EY, Ng SK, Goh CL, Lee SSJ. Recalcitrant psoriasiform dermatosis of the face: is it related to pityriasis rubra pilaris? J Cutan Pathol. 2018;45:491\u20137.","journal-title":"J Cutan Pathol"},{"key":"836_CR42","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1001\/jamadermatol.2022.2478","volume":"158","author":"KJ Rypka","year":"2022","unstructured":"Rypka KJ, Fulk TS, Afsaneh A, Miller DD, Goldfarb NI. Improvement of facial discoid dermatosis with ustekinumab treatment. JAMA Dermatol. 2022;158:1079\u201380.","journal-title":"JAMA Dermatol"},{"key":"836_CR43","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ad.2021.01.006","volume":"113","author":"F Allegue","year":"2022","unstructured":"Allegue F, Fachal C, Iglesias B, Zulaica A. Facial discoid dermatosis: a new variant of pityriasis rubra pilaris? Actas Dermosifiliogr. 2022;113:728\u201331.","journal-title":"Actas Dermosifiliogr"},{"key":"836_CR44","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jdcr.2022.12.007","volume":"32","author":"AE Davis","year":"2023","unstructured":"Davis AE, Raine BE, Swartzman I, Bogner PN, Nazareth M. Rethinking pityriasis rubra pilaris as a paraneoplastic syndrome: two cases of pityriasis rubra pilaris with concomitant underlying malignancy. JAAD Case Rep. 2023;32:90\u20135.","journal-title":"JAAD Case Rep."},{"key":"836_CR45","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/bjd.21792","volume":"187","author":"A Ji-Xu","year":"2022","unstructured":"Ji-Xu A, Lei DK, Worswick S, Maloney NJ, Kim MM, Cutler L. Patient and disease characteristics associated with psychiatric symptoms and impaired quality of life in pityriasis rubra pilaris. Br J Dermatol. 2022;187:1024\u20136.","journal-title":"Br J Dermatol"},{"key":"836_CR46","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.jaad.2019.01.061","volume":"81","author":"AB Eastham","year":"2019","unstructured":"Eastham AB, Tkachenko EY, Femia AN, Pappas-Taffer LK, Rosenbach M, Joyce CJ, et al. Pityriasis rubra pilaris: a study evaluating patient quality of life in 2 populations. J Am Acad Dermatol. 2019;81:638\u201340.","journal-title":"J Am Acad Dermatol"},{"key":"836_CR47","first-page":"185","volume":"2","author":"RC Velasco","year":"2023","unstructured":"Velasco RC, Cutler B, McCue W, Greiling TM. The comprehensive impact of pityriasis rubra pilaris onphysical symptoms, mental health, and activities ofdaily living: a mixed methods study. JEADV Clin Pract. 2023;2:185\u201392.","journal-title":"JEADV Clin Pract."},{"key":"836_CR48","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/1346-8138.14529","volume":"45","author":"L Fania","year":"2018","unstructured":"Fania L, Didona D, Pacifico V, Mariotti F, De Luca N, Abeni D, et al. Bullous pemphigoid with hyperkeratosis and palmoplantar keratoderma: three cases. J Dermatol. 2018;45:1135\u201340.","journal-title":"J Dermatol"},{"key":"836_CR49","doi-asserted-by":"publisher","first-page":"299","DOI":"10.5826\/dpc.0804a10","volume":"8","author":"AK Jha","year":"2018","unstructured":"Jha AK, Lallas A, Sonthalia S, Jhakar D, Udayan UK, Chaudhary RKP. Differentiation of pityriasis rubra pilaris from plaque psoriasis by dermoscopy. Dermatol Pract Concept. 2018;8:299\u2013302.","journal-title":"Dermatol Pract Concept."},{"key":"836_CR50","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00403-017-1727-2","volume":"309","author":"NE Abdel-Azim","year":"2017","unstructured":"Abdel-Azim NE, Ismail SA, Fathy E. Differentiation of pityriasis rubra pilaris from plaque psoriasis by dermoscopy. Arch Dermatol Res. 2017;309:311\u20134.","journal-title":"Arch Dermatol Res"},{"key":"836_CR51","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1111\/j.1365-4632.2011.04990.x","volume":"50","author":"CJ Ko","year":"2011","unstructured":"Ko CJ, Milstone LM, Choi J, McNiff JM. Pityriasis rubra pilaris: the clinical context of acantholysis and other histologic features. Int J Dermatol. 2011;50:1480\u20135.","journal-title":"Int J Dermatol"},{"key":"836_CR52","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/cup.13633","volume":"47","author":"NG Ring","year":"2020","unstructured":"Ring NG, Craiglow BG, Panse G, Antaya RJ, Ashack K, Ashack R, et al. Histopathologic findings characteristic of CARD14-associated papulosquamous eruption. J Cutan Pathol. 2020;47:425\u201330.","journal-title":"J Cutan Pathol"},{"key":"836_CR53","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ajhg.2012.05.010","volume":"91","author":"D Fuchs-Telem","year":"2012","unstructured":"Fuchs-Telem D, Sarig O, van Steensel MAM, Isakov O, Israeli S, Nousbeck J, et al. Familial pityriasis rubra pilaris is caused by mutations in CARD14. Am J Hum Genet. 2012;91:163\u201370.","journal-title":"Am J Hum Genet"},{"key":"836_CR54","doi-asserted-by":"publisher","first-page":"e389","DOI":"10.1111\/jdv.15029","volume":"32","author":"I Spoerri","year":"2018","unstructured":"Spoerri I, Herms S, Eytan O, Sarig O, Heinimann K, Sprecher E, et al. Immune-regulatory genes as possible modifiers of familial pityriasis rubra pilaris: lessons from a family with PRP and psoriasis. J Eur Acad Dermatol Venereol. 2018;32:e389\u201392.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"836_CR55","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1172\/JCI24834","volume":"115","author":"M Akiyama","year":"2005","unstructured":"Akiyama M, Sugiyama-Nakagiri Y, Sakai K, McMillan JR, Goto M, Arita K, et al. Mutations in lipid transporter ABCA12 in harlequin ichthyosis and functional recovery by corrective gene transfer. J Clin Invest. 2005;115:1777\u201384.","journal-title":"J Clin Invest"},{"key":"836_CR56","doi-asserted-by":"publisher","first-page":"382","DOI":"10.2336\/nishinihonhifu.81.382","volume":"81","author":"H Kobashi","year":"2019","unstructured":"Kobashi H, Ishimoto T, Yamamoto M, Nakajima K, Takeichi T, Akiyama S, et al. A novel missense mutation in the ABCA12 gene in Japanese siblings with congenital ichthyosis erythroderma. Nishinihon J Dermatol. 2019;81:382\u20136.","journal-title":"Nishinihon J Dermatol."},{"key":"836_CR57","doi-asserted-by":"crossref","unstructured":"Takeichi T, Hamada T, Yamamoto M, Ito Y, Kawaguchi A, Kobashi H, et al. Patients with keratinization disorders due to ABCA12 variants showing pityriasis rubra pilaris phenotypes. J Dermatol. 2023.","DOI":"10.1111\/1346-8138.16967"},{"key":"836_CR58","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.immuni.2018.05.012","volume":"49","author":"M Wang","year":"2018","unstructured":"Wang M, Zhang S, Zheng G, Huang J, Songyang Z, Zhao X, et al. Gain-of-function mutation of Card14 leads to spontaneous psoriasis-like skin inflammation through enhanced keratinocyte response to IL-17A. Immunity. 2018;49:66-79.e5.","journal-title":"Immunity"},{"key":"836_CR59","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/j.jid.2018.03.1525","volume":"138","author":"M Mellett","year":"2018","unstructured":"Mellett M, Meier B, Mohanan D, Schairer R, Cheng P, Satoh TK, et al. CARD14 gain-of-function mutation alone is sufficient to drive IL-23\/IL-17-mediated psoriasiform skin inflammation in vivo. J Invest Dermatol. 2018;138:2010\u201323.","journal-title":"J Invest Dermatol"},{"key":"836_CR60","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jid.2021.06.009","volume":"142","author":"JL Strunck","year":"2022","unstructured":"Strunck JL, Cutler B, Rajpal B, Kent G, Haynes D, Topham CA, et al. Pityriasis rubra pilaris response to IL-17A inhibition is associated with IL-17C and CCL20 protein levels. J Invest Dermatol. 2022;142:235-9.e1.","journal-title":"J Invest Dermatol"},{"key":"836_CR61","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.151911","volume":"6","author":"S Shao","year":"2021","unstructured":"Shao S, Chen J, Swindell WR, Tsoi LC, Xing X, Ma F, et al. Phospholipase A2 enzymes represent a shared pathogenic pathway in psoriasis and pityriasis rubra pilaris. JCI Insight. 2021;6: e151911.","journal-title":"JCI Insight."},{"key":"836_CR62","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/bjd.21708","volume":"187","author":"BW Boudreaux","year":"2022","unstructured":"Boudreaux BW, Pincelli TP, Bhullar PK, Patel MH, Brumfiel CM, Li X, et al. Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis. Br J Dermatol. 2022;187:650\u20138.","journal-title":"Br J Dermatol"},{"key":"836_CR63","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jid.2022.09.005","volume":"143","author":"D Haynes","year":"2023","unstructured":"Haynes D, Reiter T, Velasco R, Chang M, Kulkarni R, Kent G, et al. Pityriasis rubra pilaris transcriptomics implicate T helper 17 signaling and correlate with response to ixekizumab, with distinct gene expression profiles in nonresponders. J Invest Dermatol. 2023;143:501-4.e1.","journal-title":"J Invest Dermatol"},{"key":"836_CR64","first-page":"335","volume":"20","author":"F Filippi","year":"2022","unstructured":"Filippi F, Patrizi A, Chessa MA, Virdi A, Neri I. A novel presentation of juvenile pityriasis rubra pilaris with possible involvement of bacterial superantigens. J Dtsch Dermatol Ges. 2022;20:335\u20137.","journal-title":"J Dtsch Dermatol Ges"},{"key":"836_CR65","doi-asserted-by":"crossref","first-page":"626","DOI":"10.4103\/ijd.ijd_1016_20","volume":"67","author":"M Ishikawa","year":"2022","unstructured":"Ishikawa M, Igari S, Hiraiwa T, Hanami Y, Yamamoto T. Pityriasis rubra pilaris significantly improved after treatment for chronic focal infection. Indian J Dermatol. 2022;67:626.","journal-title":"Indian J Dermatol"},{"key":"836_CR66","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1111\/jdv.18556","volume":"37","author":"IF Aromolo","year":"2023","unstructured":"Aromolo IF, Pisapia A, Riva D, Barberi F, Marzano AV, Moltrasio C, et al. COVID-19 induced pityriasis rubra pilaris: a superantigenic disease? J Eur Acad Dermatol Venereol. 2023;37:e26\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"836_CR67","doi-asserted-by":"publisher","first-page":"e622","DOI":"10.1111\/jdv.17424","volume":"35","author":"D Kadylak","year":"2021","unstructured":"Kadylak D, Bara\u0144ska-Rybak W. Acute postinfectious pityriasis rubra pilaris as a cutaneous manifestation in COVID-19: a case report and its dermoscopic features. J Eur Acad Dermatol Venereol. 2021;35:e622\u20134.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"836_CR68","volume":"52","author":"FR Aguilar-Gamboa","year":"2021","unstructured":"Aguilar-Gamboa FR, Cubas-Alarcon D, Villegas-Chiroque M, Failoc-Rojas VE. Pityriasis rubra pilaris post-infection due COVID-19: case report. Colomb Med (Cali). 2021;52: e7014577.","journal-title":"Colomb Med (Cali)."},{"key":"836_CR69","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.jaad.2020.07.052","volume":"84","author":"A Mufti","year":"2021","unstructured":"Mufti A, Lytvyn Y, Maliyar K, Sachdeva M, Yeung J. Drugs associated with development of pityriasis rubra pilaris: a systematic review. J Am Acad Dermatol. 2021;84:1071\u201381.","journal-title":"J Am Acad Dermatol"},{"key":"836_CR70","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/ijd.15563","volume":"60","author":"T Goldberger","year":"2021","unstructured":"Goldberger T, Armoni G, Lavie D, Merims S, Maly A, Shreberk-Hassidim R. Pityriasis rubra pilaris induced by PD-1 inhibitor nivolumab. Int J Dermatol. 2021;60:1038\u20139.","journal-title":"Int J Dermatol"},{"key":"836_CR71","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/DAD.0000000000002344","volume":"45","author":"I Weber","year":"2023","unstructured":"Weber I, Gloss C, Castillo B, Smith E. Ponatinib-associated cutaneous eruptions: a case series and review of clinicopathologic findings. Am J Dermatopathol. 2023;45:64\u20138.","journal-title":"Am J Dermatopathol"},{"key":"836_CR72","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/DAD.0000000000001822","volume":"43","author":"M Mongereau","year":"2021","unstructured":"Mongereau M, Hillion B, Fouillard L, Boivin J-F, Gaudron S. Pityriasis rubra pilaris-like reaction induced by a tyrosine kinase inhibitor, the ponatinib. Am J Dermatopathol. 2021;43:394\u20135.","journal-title":"Am J Dermatopathol"},{"key":"836_CR73","doi-asserted-by":"publisher","first-page":"688","DOI":"10.4103\/ijdvl.IJDVL_918_19","volume":"86","author":"D Kamat","year":"2020","unstructured":"Kamat D, Chatterjee D, Mahajan R. Ponatinib-induced atypical pityriasis rubra pilaris-like rash. Indian J Dermatol Venereol Leprol. 2020;86:688\u201390.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"836_CR74","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14085","volume":"33","author":"M Lahouel","year":"2020","unstructured":"Lahouel M, Gammoudi R, Saidi W, Sriha B, Belajouza C, Denguezli M. Nilotinib-induced pityriasis rubra pilaris: first case report. Dermatol Ther. 2020;33: e14085.","journal-title":"Dermatol Ther"},{"issue":"23","key":"836_CR75","first-page":"00150","volume":"S0365\u20130596","author":"L Armillas-Lliteras","year":"2023","unstructured":"Armillas-Lliteras L, Iglesias-Sancho M, Altemir A, Moreno Romero JA. Pityriasis rubra pilaris induced by topical use of imiquimod 5. An Bras Dermatol. 2023;S0365\u20130596(23):00150\u20132.","journal-title":"An Bras Dermatol"},{"key":"836_CR76","doi-asserted-by":"publisher","first-page":"87","DOI":"10.5021\/ad.2019.31.1.87","volume":"31","author":"J Al-Hage","year":"2019","unstructured":"Al-Hage J, Akel R, Kurban M, Abbas O. Plasmacytoid dendritic cells in pityriasis rubra pilaris. Ann Dermatol. 2019;31:87\u201390.","journal-title":"Ann Dermatol"},{"key":"836_CR77","doi-asserted-by":"publisher","first-page":"e508","DOI":"10.1111\/jdv.18055","volume":"36","author":"PR Criado","year":"2022","unstructured":"Criado PR, Ianhez M, Rocha PS, Miot HA. Pityriasis rubra pilaris (type I) following ChAdOx1 COVID-19 vaccine: a report of two cases with successful treatment with oral isotretinoin. J Eur Acad Dermatol Venereol. 2022;36:e508\u201310.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"836_CR78","doi-asserted-by":"publisher","first-page":"e833","DOI":"10.1111\/jdv.17542","volume":"35","author":"I Llad\u00f3","year":"2021","unstructured":"Llad\u00f3 I, Butr\u00f3n B, Sampedro-Ruiz R, Fraga J, de Argila D. Pityriasis rubra pilaris after Vaxzevria\u00ae COVID-19 vaccine. J Eur Acad Dermatol Venereol. 2021;35:e833\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"836_CR79","doi-asserted-by":"publisher","first-page":"e675","DOI":"10.1111\/jdv.18214","volume":"36","author":"T Gambichler","year":"2022","unstructured":"Gambichler T, Scheel CH, Arafat Y, Kautz O, Boms S. Erythrodermic pityriasis rubra pilaris after SARS-CoV-2 vaccination with concomitant COVID-19 infection. J Eur Acad Dermatol Venereol. 2022;36:e675\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"836_CR80","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jdcr.2023.03.003","volume":"35","author":"P Zhao","year":"2023","unstructured":"Zhao P, Rusu CA, Schenck OL. Pityriasis rubra pilaris following COVID-19 vaccination successfully treated with ixekizumab. JAAD Case Rep. 2023;35:52\u20136.","journal-title":"JAAD Case Rep."},{"key":"836_CR81","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/DAD.0000000000002369","volume":"45","author":"YA Liu","year":"2023","unstructured":"Liu YA, Dai J, Nagarajan P, Torres-Cabala CA, Aung PP, Prieto VG, et al. Pityriasis rubra pilaris after Moderna COVID-19 vaccination: a case report and literature review. Am J Dermatopathol. 2023;45:185\u20138.","journal-title":"Am J Dermatopathol"},{"key":"836_CR82","doi-asserted-by":"publisher","first-page":"e287","DOI":"10.1111\/jdv.18768","volume":"37","author":"L-W Zhang","year":"2023","unstructured":"Zhang L-W, Wang W-J, Fu L-X, Lu Y-H, Chen T, Xu R-H. Pityriasis rubra pilaris following inactivated SARS-CoV-2 vaccine (CoronaVac). J Eur Acad Dermatol Venereol. 2023;37:e287\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"836_CR83","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15899","volume":"35","author":"SBL Gamonal","year":"2022","unstructured":"Gamonal SBL, Marques NCV, Pereira HMB, Gamonal ACC. Pityriasis rubra pilaris (type I) following administration of the BNT162b2 mRNA COVID-19 vaccine: successful treatment with ustekinumab and acitretin. Dermatol Ther. 2022;35: e15899.","journal-title":"Dermatol Ther"},{"key":"836_CR84","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15791","volume":"35","author":"N Hlaca","year":"2022","unstructured":"Hlaca N, Zagar T, Kastelan M, Peternel S, Brajac I, Dujmovic-Hasanbegovic K, et al. Pityriasis rubra pilaris following booster dose of mRNA (Pfizer-BioNTech) COVID-19 vaccine. Dermatol Ther. 2022;35: e15791.","journal-title":"Dermatol Ther"},{"key":"836_CR85","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.139","volume":"3","author":"Y-T Liu","year":"2022","unstructured":"Liu Y-T, Wang S-S. Ixekizumab successfully treated severe pityriasis rubra pilaris after COVID-19 vaccination. Skin Health Dis. 2022;3: e139.","journal-title":"Skin Health Dis."},{"key":"836_CR86","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1111\/jocd.14933","volume":"21","author":"A Arora","year":"2022","unstructured":"Arora A, Mohta A, Ghiya BC, Kumar JV. Acute postinfectious type III pityriasis rubra pilaris as a cutaneous manifestation in COVID-19: decoding a possible trigger!! J Cosmet Dermatol. 2022;21:3206\u20137.","journal-title":"J Cosmet Dermatol"},{"key":"836_CR87","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jdcr.2022.04.020","volume":"24","author":"M Wada","year":"2022","unstructured":"Wada M, Lee S, Curnow P, Simpson I, Mar A. A case of pityriasis rubra pilaris following AstraZeneca COVID-19 vaccine. JAAD Case Rep. 2022;24:74\u20137.","journal-title":"JAAD Case Rep."},{"key":"836_CR88","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jdcr.2022.03.013","volume":"23","author":"EM Ajebo","year":"2022","unstructured":"Ajebo EM, Howard JD, Anand D, Davis LS. Pityriasis rubra pilaris potentially triggered by messenger RNA-1273 COVID vaccine. JAAD Case Rep. 2022;23:114\u20136.","journal-title":"JAAD Case Rep."},{"key":"836_CR89","doi-asserted-by":"publisher","first-page":"e15455","DOI":"10.1111\/dth.15455","volume":"35","author":"LT Fern\u00e1ndez","year":"2022","unstructured":"Fern\u00e1ndez LT, P\u00e9rez-Garza DM, delaO-Escamilla A, Yamallel-Ortega LA, Cuellar-Barboza A, Ocampo-Candiani J, et al. Pityriasis rubra pilaris in association with inactivated SARS-CoV-2 vaccine (CoronaVac). Dermatol Ther. 2022;35:e15455.","journal-title":"Dermatol Ther"},{"key":"836_CR90","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/ced.14970","volume":"47","author":"A Sechi","year":"2022","unstructured":"Sechi A, Pierobon E, Pezzolo E, Germi L, Trevisan G, Zardo D, et al. Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: unravelling a possible common trigger, the COVID-19 vaccine. Clin Exp Dermatol. 2022;47:437\u201340.","journal-title":"Clin Exp Dermatol"},{"key":"836_CR91","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3233\/JRS-210048","volume":"32","author":"MK Sahni","year":"2021","unstructured":"Sahni MK, Roy K, Asati DP, Khurana U. An old entity, a new trigger: post COVID-19 vaccine pityriasis rubra pilaris. Int J Risk Saf Med. 2021;32:261\u20134.","journal-title":"Int J Risk Saf Med"},{"key":"836_CR92","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/ced.14878","volume":"47","author":"MK Hunjan","year":"2022","unstructured":"Hunjan MK, Roberts C, Karim S, Hague J. Pityriasis rubra pilaris-like eruption following administration of the BNT163b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine. Clin Exp Dermatol. 2022;47:188\u201390.","journal-title":"Clin Exp Dermatol"},{"key":"836_CR93","doi-asserted-by":"crossref","unstructured":"Gambichler T. Clinical characteristics of patients with pityriasis rubra pilaris following SARS-CoV-2 vaccination. J Eur Acad Dermatol Venereol. 2023.","DOI":"10.1111\/jdv.19046"},{"key":"836_CR94","doi-asserted-by":"publisher","first-page":"469","DOI":"10.4103\/idoj.IDOJ_363_18","volume":"10","author":"RK Sharma","year":"2019","unstructured":"Sharma RK, Gupta M, Gulati A. Koebner phenomenon in classic juvenile onset pityriasis rubra pilaris. Indian Dermatol Online J. 2019;10:469\u201370.","journal-title":"Indian Dermatol Online J"},{"key":"836_CR95","first-page":"47","volume":"27","author":"EM Acar","year":"2019","unstructured":"Acar EM, Has S, Kilitci A, Kemeriz F. Circumscribed juvenile pityriasis rubra pilaris (type 4) Koebnerising after a hot water burn: mild disease with maximum Koebner response. Acta Dermatovenerol Croat. 2019;27:47\u20139.","journal-title":"Acta Dermatovenerol Croat"},{"key":"836_CR96","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/ced.13718","volume":"44","author":"G Genovese","year":"2019","unstructured":"Genovese G, Muratori S, Berti E, Marzano AV. Bullous erythroderma: novel association of pityriasis rubra pilaris with bullous pemphigoid. Clin Exp Dermatol. 2019;44:73\u20135.","journal-title":"Clin Exp Dermatol"},{"key":"836_CR97","doi-asserted-by":"publisher","first-page":"adv00674","DOI":"10.2340\/actadv.v102.1289","volume":"102","author":"I Gasslitter","year":"2022","unstructured":"Gasslitter I, L\u00f6ffler-Ragg J, Schmidt E, Schmuth M, Gruber R. Coincidence of bullous pemphigoid and pityriasis rubra pilaris. Acta Derm Venereol. 2022;102:adv00674.","journal-title":"Acta Derm Venereol"},{"key":"836_CR98","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1111\/1346-8138.16711","volume":"50","author":"N Sugihara","year":"2023","unstructured":"Sugihara N, Kamiya K, Nakano N, Suzuki M, Maekawa T, Murata S, et al. A case of bullous pemphigoid developing after ixekizumab therapy for pityriasis rubra pilaris. J Dermatol. 2023;50:e185\u20136.","journal-title":"J Dermatol"},{"key":"836_CR99","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1684\/ejd.2020.3879","volume":"30","author":"C Kromer","year":"2020","unstructured":"Kromer C, Lippert U, Sch\u00f6n MP, M\u00f6ssner R. Treatment of pityriasis rubra pilaris: a case series of 28 patients. Eur J Dermatol. 2020;30:569\u201379.","journal-title":"Eur J Dermatol"},{"key":"836_CR100","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1684\/ejd.2019.3641","volume":"29","author":"C Engelmann","year":"2019","unstructured":"Engelmann C, Elsner P, Miguel D. Treatment of pityriasis rubra pilaris type I: a systematic review. Eur J Dermatol. 2019;29:524\u201337.","journal-title":"Eur J Dermatol"},{"key":"836_CR101","first-page":"243","volume":"17","author":"C Kromer","year":"2019","unstructured":"Kromer C, Sabat R, Celis D, M\u00f6ssner R. Systemic therapies of pityriasis rubra pilaris: a systematic review. J Dtsch Dermatol Ges. 2019;17:243\u201359.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"21","key":"836_CR102","first-page":"00164","volume":"S1578\u20132190","author":"MS Zegpi-Trueba","year":"2021","unstructured":"Zegpi-Trueba MS, Navajas-Galimany L, Gonz\u00e1lez S, Ram\u00edrez-Cornejo C. Acute postinfection pityriasis rubra pilaris: excellent response to emollients and topical corticosteroids. Actas Dermosifiliogr (Engl Ed). 2021;S1578\u20132190(21):00164\u20135.","journal-title":"Actas Dermosifiliogr (Engl Ed)."},{"key":"836_CR103","first-page":"340","volume":"6","author":"S Gregoriou","year":"2007","unstructured":"Gregoriou S, Argyriou G, Christofidou E, Vranou A, Rigopoulos D. Treatment of pityriasis rubra pilaris with pimecrolimus cream 1%. J Drugs Dermatol. 2007;6:340\u20132.","journal-title":"J Drugs Dermatol"},{"key":"836_CR104","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/j.1365-2133.1994.tb13121.x","volume":"130","author":"PC Van de Kerkhof","year":"1994","unstructured":"Van de Kerkhof PC, Steijlen PM. Topical treatment of pityriasis rubra pilaris with calcipotriol. Br J Dermatol. 1994;130:675\u20138.","journal-title":"Br J Dermatol"},{"key":"836_CR105","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/S0190-9622(82)70061-1","volume":"6","author":"LA Goldsmith","year":"1982","unstructured":"Goldsmith LA, Weinrich AE, Shupack J. Pityriasis rubra pilaris response to 13-cis-retinoic acid (isotretinoin). J Am Acad Dermatol. 1982;6:710\u20135.","journal-title":"J Am Acad Dermatol"},{"key":"836_CR106","doi-asserted-by":"crossref","unstructured":"Ringin S, Baker CS, Foley P, Daniel BS. Pityriasis rubra pilaris treatment options: a retrospective case series from a tertiary hospital. Dermatol Ther. 2021;34:e15128.","DOI":"10.1111\/dth.15128"},{"key":"836_CR107","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/jdv.15455","volume":"33","author":"B G\u00e1l","year":"2019","unstructured":"G\u00e1l B, G\u00f6bl\u00f6s A, Danis J, Farkas K, Sul\u00e1k A, Varga E, et al. The management and genetic background of pityriasis rubra pilaris: a single-centre experience. J Eur Acad Dermatol Venereol. 2019;33:944\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"836_CR108","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s40257-022-00700-4","volume":"23","author":"TP Joshi","year":"2022","unstructured":"Joshi TP, Wang HY, Athukuri P, Bohac S, Farr MA, Hinson D, et al. Biologic therapies for the management of cutaneous findings in genodermatoses: a review. Am J Clin Dermatol. 2022;23:673\u201388.","journal-title":"Am J Clin Dermatol"},{"key":"836_CR109","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jaad.2018.03.036","volume":"79","author":"M Napolitano","year":"2018","unstructured":"Napolitano M, Abeni D, Didona B. Biologics for pityriasis rubra pilaris treatment: a review of the literature. J Am Acad Dermatol. 2018;79:353-9.e11.","journal-title":"J Am Acad Dermatol"},{"key":"836_CR110","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13060","volume":"32","author":"NJ Maloney","year":"2019","unstructured":"Maloney NJ, Kim MM, Nguyen KA, Hisaw LD, Worswick S. Patient experiences with biologics and apremilast in pityriasis rubra pilaris: a patient survey. Dermatol Ther. 2019;32: e13060.","journal-title":"Dermatol Ther"},{"key":"836_CR111","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1001\/jamadermatol.2020.0932","volume":"156","author":"D Haynes","year":"2020","unstructured":"Haynes D, Strunck JL, Topham CA, Ortega-Loayza AG, Kent G, Cassidy PB, et al. Evaluation of ixekizumab treatment for patients with pityriasis rubra pilaris: a single-arm trial. JAMA Dermatol. 2020;156:668\u201375.","journal-title":"JAMA Dermatol"},{"key":"836_CR112","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jdcr.2018.05.006","volume":"4","author":"MD Heibel","year":"2018","unstructured":"Heibel MD, Heibel HD. Successful treatment of type I pityriasis rubra pilaris with ixekizumab. JAAD Case Rep. 2018;4:774\u20136.","journal-title":"JAAD Case Rep."},{"key":"836_CR113","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000488902","volume":"10","author":"K Hanfstingl","year":"2018","unstructured":"Hanfstingl K, Pekar-Lukacs A, Motz R, Guenova E, Hoetzenecker W. Successful treatment of pityriasis rubra pilaris with ixekizumab. Case Rep Dermatol. 2018;10:97\u2013100.","journal-title":"Case Rep Dermatol"},{"key":"836_CR114","first-page":"367","volume":"101","author":"L Bonomo","year":"2018","unstructured":"Bonomo L, Levitt JO. Secukinumab emerges as a rapidly effective therapy for pityriasis rubra pilaris. Cutis. 2018;101:367\u20139.","journal-title":"Cutis"},{"key":"836_CR115","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/ajd.13614","volume":"62","author":"K Simpson","year":"2021","unstructured":"Simpson K, Dolianitis C. A case of treatment-resistant pityriasis rubra pilaris responsive to secukinumab. Australas J Dermatol. 2021;62:441\u20132.","journal-title":"Australas J Dermatol"},{"key":"836_CR116","first-page":"501","volume":"156","author":"M Papini","year":"2021","unstructured":"Papini M, Russo A, Natalini Y, Troiani L, Cassiani L. Secukinumab is an effective and safe treatment for refractory pityriasis rubra pilaris. Ital J Dermatol Venerol. 2021;156:501\u20132.","journal-title":"Ital J Dermatol Venerol."},{"key":"836_CR117","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1111\/bjd.18263","volume":"181","author":"D Cole","year":"2019","unstructured":"Cole D, Mohammad T, Lim H. Rapid response of pityriasis rubra pilaris with psoriasis overlap to secukinumab. Br J Dermatol. 2019;181:1331\u20132.","journal-title":"Br J Dermatol"},{"key":"836_CR118","doi-asserted-by":"crossref","first-page":"601","DOI":"10.4103\/ijd.ijd_1079_21","volume":"67","author":"H Albela","year":"2022","unstructured":"Albela H, Lee WQ, Nordin SN, Gopinathan LP, Ramli MNA, Leong KF. Juvenile pityriasis rubra pilaris in a 4-year-old child treated successfully with secukinumab. Indian J Dermatol. 2022;67:601\u20133.","journal-title":"Indian J Dermatol"},{"key":"836_CR119","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1111\/ced.15353","volume":"47","author":"Y-H Xu","year":"2022","unstructured":"Xu Y-H, Dong D-D, Lin Y-F, Wang Q, Huang L-M, Shi J-Q. Successful treatment of severe pityriasis rubra pilaris with secukinumab in a 3-year-old boy. Clin Exp Dermatol. 2022;47:2043\u20135.","journal-title":"Clin Exp Dermatol"},{"key":"836_CR120","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jdcr.2018.02.007","volume":"4","author":"T Wain","year":"2018","unstructured":"Wain T, Choy B, Satchell AC, Woods JA, Frew JW. Secukinumab in pityriasis rubra pilaris: a case series demonstrating variable response and the need for minimal clinical datasets. JAAD Case Rep. 2018;4:500\u20135.","journal-title":"JAAD Case Rep."},{"key":"836_CR121","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/1346-8138.14709","volume":"46","author":"T Matsuda","year":"2019","unstructured":"Matsuda T, Yamazaki F, Ueda-Hayakawa I, Kambe N, Okamoto H. Case of pityriasis rubra pilaris progressed to generalized erythroderma following blockade of interleukin-17A, but improved after blockade of interleukin-12\/23 p40. J Dermatol. 2019;46:70\u20132.","journal-title":"J Dermatol"},{"key":"836_CR122","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1111\/ijd.15219","volume":"60","author":"V Amat-Samaranch","year":"2021","unstructured":"Amat-Samaranch V, Cubir\u00f3 X, Tubau C, Garcia-Melendo C, Puig L. Response of pityriasis rubra pilaris to brodalumab after primary failure to ustekinumab. Int J Dermatol. 2021;60:e112\u20134.","journal-title":"Int J Dermatol"},{"key":"836_CR123","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1111\/ajd.13215","volume":"61","author":"A De Rosa","year":"2020","unstructured":"De Rosa A, Gambardella A, Licata G, Alfano R, Argenziano G. Successful treatment of pityriasis rubra pilaris with brodalumab. Australas J Dermatol. 2020;61:e249\u201351.","journal-title":"Australas J Dermatol"},{"key":"836_CR124","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/ijd.14857","volume":"59","author":"C De Felice","year":"2020","unstructured":"De Felice C, Graceffa D, Morrone A, Bonifati C. Familial pityriasis rubra pilaris successfully treated with brodalumab. Int J Dermatol. 2020;59:885\u20137.","journal-title":"Int J Dermatol"},{"key":"836_CR125","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.6413","volume":"10","author":"M Nishimura","year":"2022","unstructured":"Nishimura M, Kondo M, Habe K, Hayashi A, Yamanaka K. Successful treatment with cyclosporine and guselkumab for pityriasis rubra pilaris. Clin Case Rep. 2022;10: e6413.","journal-title":"Clin Case Rep."},{"key":"836_CR126","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/1346-8138.14114","volume":"45","author":"M Napolitano","year":"2018","unstructured":"Napolitano M, Lembo L, Fania L, Abeni D, Didona D, Didona B. Ustekinumab treatment of pityriasis rubra pilaris: a report of five cases. J Dermatol. 2018;45:202\u20136.","journal-title":"J Dermatol"},{"key":"836_CR127","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jdcr.2017.09.010","volume":"4","author":"L Bonomo","year":"2018","unstructured":"Bonomo L, Raja A, Tan K, Guttman-Yassky E. Successful treatment of juvenile pityriasis rubra pilaris with ustekinumab in a 7-year-old girl. JAAD Case Rep. 2018;4:206\u201310.","journal-title":"JAAD Case Rep."},{"key":"836_CR128","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-235287","volume":"14","author":"RM Nielsen","year":"2021","unstructured":"Nielsen RM, Gram SB, Bygum A. Identification of a pathogenic CARD14 mutation in a 70-year-old woman with pityriasis rubra pilaris: when genetic diagnosis influences choice of treatment strategy. BMJ Case Rep. 2021;14: e235287.","journal-title":"BMJ Case Rep"},{"key":"836_CR129","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/ajd.13925","volume":"63","author":"JP Pham","year":"2022","unstructured":"Pham JP, Allen N, Smith A. Efficacy of ustekinumab and guselkumab in treatment refractory pityriasis rubra pilaris: a case series. Australas J Dermatol. 2022;63:522\u20134.","journal-title":"Australas J Dermatol"},{"key":"836_CR130","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1111\/ddg.13550","volume":"16","author":"R Arag\u00f3n-Miguel","year":"2018","unstructured":"Arag\u00f3n-Miguel R, Prieto-Barrios M, Calleja-Algarra A, Velasco-Tamariz V, Andres-Lencina JJ, Ortiz-Romero P, et al. Refractory pityriasis rubra pilaris with good response after treatment with ustekinumab. J Dtsch Dermatol Ges. 2018;16:1022\u20135.","journal-title":"J Dtsch Dermatol Ges"},{"key":"836_CR131","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/ced.13626","volume":"43","author":"N Ismail","year":"2018","unstructured":"Ismail N, Callander J, Williams M, Anstey AV. Erythrodermic pityriasis rubra pilaris managed at home: intensive community care followed by ustekinumab. Clin Exp Dermatol. 2018;43:749\u201351.","journal-title":"Clin Exp Dermatol"},{"key":"836_CR132","doi-asserted-by":"crossref","unstructured":"Cook E, Tran KW, Kollipara S, Tarbox M, Akin R. A case of resistant pityriasis ribra pilaris responsive to combination acitrentin and ustekinumab. Dermatol Online J. 2020;26:13030\/qt1712g0gm.","DOI":"10.5070\/D3263047986"},{"key":"836_CR133","doi-asserted-by":"crossref","unstructured":"DeBiasio C, Cyr J, Ayroud Y, Glassman SJ. A case of classic adult pityriasis rubra pilaris successfully treated with a combination of acitretin and ustekinumab: a case report. SAGE Open Med Case Rep. 2022;10:2050313X221093453.","DOI":"10.1177\/2050313X221093453"},{"key":"836_CR134","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/pde.14994","volume":"39","author":"M Katharina","year":"2022","unstructured":"Katharina M, Sylvia S, Matthias B, Ulrich M, Martin L. Successful treatment of a child\u2019s pityriasis rubra pilaris (PRP) with ustekinumab and acitretin. Pediatr Dermatol. 2022;39:659\u201361.","journal-title":"Pediatr Dermatol"},{"key":"836_CR135","doi-asserted-by":"publisher","first-page":"54","DOI":"10.14797\/mdcvj.1076","volume":"18","author":"M Abdelnabi","year":"2022","unstructured":"Abdelnabi M, ElNawaa S, Benjanuwattra J, Elmassry M, Nair N. Ustekinumab-induced fatal acute heart failure in a young female: a case report. Methodist Debakey Cardiovasc J. 2022;18:54\u20138.","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"836_CR136","volume":"7","author":"CI Kalogeropoulos","year":"2020","unstructured":"Kalogeropoulos CI, Papathanasiou KA, Tsagkaraki I, Giannopoulos G, Bamias A, Boutati EI. A case of meningococcal and HSV-2 meningitis in a patient being treated with ustekinumab for pityriasis rubra pilaris. Eur J Case Rep Intern Med. 2020;7: 001615.","journal-title":"Eur J Case Rep Intern Med."},{"key":"836_CR137","doi-asserted-by":"publisher","first-page":"e728","DOI":"10.1111\/jdv.16548","volume":"34","author":"LM Nieto-Benito","year":"2020","unstructured":"Nieto-Benito LM, Baniandr\u00e9s-Rodr\u00edguez O, Moreno-Torres A, Hern\u00e1ndez-Mart\u00edn A, Torrelo-Fern\u00e1ndez A, Campos-Dom\u00ednguez M. Clinical response to ustekinumab in CARD14-associated papulosquamous eruption (CAPE) with a new missense mutation in CARD14: a case report and systematic review. J Eur Acad Dermatol Venereol. 2020;34:e728\u201330.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"836_CR138","doi-asserted-by":"crossref","unstructured":"Nogueira M, Reis J, Abreu M, Coelho A, Reis CF, Machado S. A child with CARD14-associated papulosquamous eruption (CAPE) successfully treated with ustekinumab. Pediatr Dermatol. 2023;40:1104\u20136.","DOI":"10.1111\/pde.15336"},{"key":"836_CR139","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15939","volume":"35","author":"AE Kiszewski","year":"2022","unstructured":"Kiszewski AE, De Almeida HL. Successful treatment with ustekinumab in CARD14-associated papulosquamous eruption in a Brazilian child. Dermatol Ther. 2022;35: e15939.","journal-title":"Dermatol Ther"},{"key":"836_CR140","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1111\/jdv.18516","volume":"37","author":"A-L Fouarge","year":"2023","unstructured":"Fouarge A-L, Cuvelier M, Roquet-Gravy C, de Montjoye L, Baeck M. Successful treatment of pityriasis rubra pilaris with risankizumab, a IL-23\/p19 antagonist. J Eur Acad Dermatol Venereol. 2023;37:e106\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"836_CR141","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1007\/s13555-023-01005-y","volume":"13","author":"M Ko\u0142t-Kami\u0144ska","year":"2023","unstructured":"Ko\u0142t-Kami\u0144ska M, Osi\u0144ska A, Kaznowska E, Reich A. Successful treatment of pityriasis rubra pilaris with risankizumab in children. Dermatol Ther (Heidelb). 2023;13:2431\u201341.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"836_CR142","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15112","volume":"34","author":"R Balestri","year":"2021","unstructured":"Balestri R, Magnano M, Girardelli CR, Rech G. Is risankizumab effective in the treatment of pityriasis rubra pilaris? Dermatol Ther. 2021;34: e15112.","journal-title":"Dermatol Ther"},{"key":"836_CR143","first-page":"1207","volume":"19","author":"C Kromer","year":"2021","unstructured":"Kromer C, Sch\u00f6n MP, M\u00f6ssner R. Treatment of pityriasis rubra pilaris with risankizumab in two cases. J Dtsch Dermatol Ges. 2021;19:1207\u20139.","journal-title":"J Dtsch Dermatol Ges"},{"key":"836_CR144","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19681","volume":"184","author":"J Ricar","year":"2021","unstructured":"Ricar J, Cetkovska P. Successful treatment of refractory extensive pityriasis rubra pilaris with risankizumab. Br J Dermatol. 2021;184: e148.","journal-title":"Br J Dermatol"},{"key":"836_CR145","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/ced.14715","volume":"46","author":"E Brocco","year":"2021","unstructured":"Brocco E, Laffitte E. Risankizumab for pityriasis rubra pilaris. Clin Exp Dermatol. 2021;46:1322\u20134.","journal-title":"Clin Exp Dermatol"},{"key":"836_CR146","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/bjd.20061","volume":"185","author":"B Duarte","year":"2021","unstructured":"Duarte B, Paiva Lopes MJ. Response to: \u201cSuccessful treatment of refractory extensive pityriasis rubra pilaris with risankizumab.\u201d Br J Dermatol. 2021;185:235\u20136.","journal-title":"Br J Dermatol"},{"key":"836_CR147","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14403","volume":"33","author":"H Nagai","year":"2020","unstructured":"Nagai H, Jimbo H, Matsuura S, Tatsuoka S, Shiraki E, Nishigori C. Successful treatment of pityriasis rubra pilaris with guselkumab: serum CCL20 as a potential marker for the disease activity. Dermatol Ther. 2020;33: e14403.","journal-title":"Dermatol Ther"},{"key":"836_CR148","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1001\/jamadermatol.2019.2774","volume":"155","author":"AC Pilz","year":"2019","unstructured":"Pilz AC, Seiringer P, Biedermann T, Eyerich K. Treatment of pityriasis rubra pilaris with guselkumab. JAMA Dermatol. 2019;155:1424\u20136.","journal-title":"JAMA Dermatol"},{"key":"836_CR149","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1111\/ced.14790","volume":"46","author":"G Licata","year":"2021","unstructured":"Licata G, Gambardella A, Calabrese G, Pagliuca F, Alfano R, Argenziano G. Refractory type I pityriasis rubra pilaris treated with tildrakizumab. Clin Exp Dermatol. 2021;46:1594\u20135.","journal-title":"Clin Exp Dermatol"},{"key":"836_CR150","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/ajd.13753","volume":"63","author":"SS Zagarella","year":"2022","unstructured":"Zagarella SS, Jiang KW. Successful treatment of pityriasis rubra pilaris with tildrakizumab. Australas J Dermatol. 2022;63:120\u20131.","journal-title":"Australas J Dermatol"},{"key":"836_CR151","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1365-2230.1991.tb00341.x","volume":"16","author":"JT Lim","year":"1991","unstructured":"Lim JT, Tham SN. Pityriasis rubra pilaris in Singapore. Clin Exp Dermatol. 1991;16:181\u20134.","journal-title":"Clin Exp Dermatol"},{"key":"836_CR152","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S0190-9622(94)70271-3","volume":"31","author":"CH Dicken","year":"1994","unstructured":"Dicken CH. Treatment of classic pityriasis rubra pilaris. J Am Acad Dermatol. 1994;31:997\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"836_CR153","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1016\/j.cellsig.2014.05.014","volume":"26","author":"PH Schafer","year":"2014","unstructured":"Schafer PH, Parton A, Capone L, Cedzik D, Brady H, Evans JF, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26:2016\u201329.","journal-title":"Cell Signal"},{"key":"836_CR154","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/1203475417733464","volume":"22","author":"E Molina-Figuera","year":"2018","unstructured":"Molina-Figuera E, Gonz\u00e1lez-Cantero \u00c1, Mart\u00ednez-Lorenzo E, S\u00e1nchez-Moya A-I, Garc\u00eda-Olmedo O, G\u00f3mez-Dorado B, et al. Successful treatment of refractory type 1 pityriasis rubra pilaris with apremilast. J Cutan Med Surg. 2018;22:104\u20135.","journal-title":"J Cutan Med Surg"},{"key":"836_CR155","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14714","volume":"34","author":"E Inoue","year":"2021","unstructured":"Inoue E, Arase N, Hanaoka Y, Tanemura A, Fujimoto M. The beneficial effect of a PDE4 inhibitor in a patient with juvenile-onset intractable pityriasis rubra pilaris without CARD14 mutation. Dermatol Ther. 2021;34: e14714.","journal-title":"Dermatol Ther"},{"key":"836_CR156","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2340\/00015555-2995","volume":"98","author":"M Cho","year":"2018","unstructured":"Cho M, Honda T, Ueshima C, Kataoka T, Otsuka A, Kabashima K. A case of pityriasis rubra pilaris treated successfully with the phosphodiesterase-4 inhibitor apremilast. Acta Derm Venereol. 2018;98:975\u20136.","journal-title":"Acta Derm Venereol"},{"key":"836_CR157","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1684\/ejd.2017.3187","volume":"28","author":"L Pellonnet","year":"2018","unstructured":"Pellonnet L, Beltzung F, Franck F, Rouanet J, D\u2019incan M. A case of severe pityriasis rubra pilaris with a dramatic response to apremilast. Eur J Dermatol. 2018;28:128\u20139.","journal-title":"Eur J Dermatol"},{"key":"836_CR158","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jdcr.2020.01.013","volume":"6","author":"S Chapman","year":"2020","unstructured":"Chapman S, Adelman M, Sullivan A, Mancuso J, Lim HW. Apremilast-associated drug reaction with eosinophilia and systemic symptoms. JAAD Case Rep. 2020;6:302\u20134.","journal-title":"JAAD Case Rep."},{"key":"836_CR159","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","volume":"76","author":"W Damsky","year":"2017","unstructured":"Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76:736\u201344.","journal-title":"J Am Acad Dermatol"},{"key":"836_CR160","doi-asserted-by":"crossref","unstructured":"Ying Y, Yu-Hua L, Xiao-Yan W, Su-Chun H. A case of pityriasis rubra pilaris treated with tofacitinib after failure with acitretin and ixekizumab. Australas J Dermatol. 2023;64:445\u20137.","DOI":"10.1111\/ajd.14076"},{"key":"836_CR161","doi-asserted-by":"crossref","unstructured":"Saad M, Spurr A, Lipson J. Pityriasis rubra pilaris partially responsive to treatment with upadacitinib: a case report. SAGE Open Med Case Rep. 2023;11:2050313X231160927.","DOI":"10.1177\/2050313X231160927"},{"key":"836_CR162","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jdcr.2023.03.004","volume":"35","author":"EJ Song","year":"2023","unstructured":"Song EJ, Al-Saedy MA, Bouch\u00e9 N. Refractory pityriasis rubra pilaris treated with upadacitinib. JAAD Case Rep. 2023;35:112\u20134.","journal-title":"JAAD Case Rep."},{"key":"836_CR163","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s40257-022-00701-3","volume":"23","author":"SB Elmariah","year":"2022","unstructured":"Elmariah SB, Smith JS, Merola JF. JAK in the [black] box: a dermatology perspective on systemic JAK inhibitor safety. Am J Clin Dermatol. 2022;23:427\u201331.","journal-title":"Am J Clin Dermatol"},{"key":"836_CR164","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2340\/00015555-2885","volume":"98","author":"L Koch","year":"2018","unstructured":"Koch L, Sch\u00f6ffl C, Aberer W, Massone C. Methotrexate treatment for pityriasis rubra pilaris: a case series and literature review. Acta Derm Venereol. 2018;98:501\u20135.","journal-title":"Acta Derm Venereol"},{"key":"836_CR165","doi-asserted-by":"publisher","first-page":"e391","DOI":"10.1016\/j.jaad.2020.02.075","volume":"83","author":"J Lee","year":"2020","unstructured":"Lee J, Iyengar S, Zinn Z. Pulsed dye laser as an adjunctive treatment for therapy-resistant pityriasis rubra pilaris. J Am Acad Dermatol. 2020;83:e391\u20132.","journal-title":"J Am Acad Dermatol"},{"key":"836_CR166","doi-asserted-by":"crossref","unstructured":"Shao C, Velasco R, Greiling TM. The individual pityriasis rubra pilaris area and severity index (iPRPASI): validity, reliability, and responsiveness of a novel patient-reported severity tool. Arch Dermatol Res. 2023.","DOI":"10.1007\/s00403-023-02682-7"},{"key":"836_CR167","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/jamadermatol.2013.4773","volume":"150","author":"AB Eastham","year":"2014","unstructured":"Eastham AB, Femia AN, Qureshi A, Vleugels RA. Treatment options for pityriasis rubra pilaris including biologic agents: a retrospective analysis from an academic medical center. JAMA Dermatol. 2014;150:92\u20134.","journal-title":"JAMA Dermatol"},{"key":"836_CR168","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1046\/j.1365-2133.2003.05394.x","volume":"149","author":"T Wetzig","year":"2003","unstructured":"Wetzig T, Sticherling M. Juvenile pityriasis rubra pilaris: successful treatment with ciclosporin. Br J Dermatol. 2003;149:202\u20133.","journal-title":"Br J Dermatol"},{"key":"836_CR169","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2340\/00015555-1928","volume":"95","author":"PM Amann","year":"2015","unstructured":"Amann PM, Susic M, Gl\u00fcder F, Berger H, Krapf W, L\u00f6ffler H. Alitretinoin (9-cis retinoic acid) is effective against pityriasis rubra pilaris: a retrospective clinical study. Acta Derm Venereol. 2015;95:329\u201331.","journal-title":"Acta Derm Venereol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-023-00836-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-023-00836-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-023-00836-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T22:35:43Z","timestamp":1730932543000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-023-00836-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,30]]},"references-count":169,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["836"],"URL":"https:\/\/doi.org\/10.1007\/s40257-023-00836-x","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,30]]},"assertion":[{"value":"4 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Tejas P. Joshi and Madeleine Duvic have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Articles used in this review are available in the public domain.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"TPJ conceived the idea for this review, performed the literature search, and wrote the first draft of the manuscript. MD provided expert guidance and critically revised the work. Both authors read and approved the final submitted version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}